AesMed is proud to continue its long-standing tradition of participation in the Korean Society of Hair Restoration Surgery (KSHRS) Conference, one of the most prestigious and renowned hair transplant conferences in Korea.
This year marks another successful year of involvement, as AesMed has been a proud participant every year since 2012.
The KSHRS Conference has always provided AesMed with the invaluable opportunity to connect with leading experts in the field of hair loss treatment.
The conference serves as a platform to showcase the latest advancements in hair restoration, and this year was no exception.
We were thrilled to present CytoMesopecia, our cutting-edge cytokine-based therapy for hair loss, alongside our highly impactful AGF39™ product.
AGF39™, AesMed’s flagship cytokines therapy, has revolutionized the way we approach hair loss treatment.
It is formulated with seven different cytokines, targeting the underlying biological mechanisms of hair loss and promoting hair follicle regeneration.
For over 18 years, AGF39™ has been a leading mesotherapy solution in both Korea and Japan, trusted by clinics and dermatologists for its proven efficacy and safety.
At the KSHRS Conference, we had the opportunity to showcase how CytoMesopecia and AGF39™ work together to provide comprehensive and effective solutions for alopecia.
Many medical professionals who actively incorporate CytoMesopecia into their clinical practice joined us to celebrate the remarkable strides made in hair restoration.
We were also honored to engage with key opinion leaders and partner hospitals, who have played a significant role in the development and application of CytoMesopecia and AGF39™.
These collaborations are essential as we work to push the boundaries of hair restoration, offering breakthrough solutions to patients worldwide.
AesMed is committed to advancing the standard of care in hair restoration, and we are excited to continue working alongside these esteemed professionals.
Together, we aim to further elevate the quality of treatment and enhance the lives of those affected by hair loss across the globe.
Stay tuned for more updates as AesMed leads the way in hair loss treatment innovations!
Key Highlights of AesMed’s Participation at KSHRS 2025:
• Showcased CytoMesopecia and AGF39™, our innovative cytokines therapy.
• Explored the clinical applications and scientific evidence supporting AGF39™.
• Engaged with top professionals and key opinion leaders in the field of hair restoration.
• Celebrated advancements in hair loss treatment with partner hospitals and research institutions.
• Continued commitment to improving the global standard of care in hair restoration.
What’s Next?
AesMed is excited to continue contributing to the field of hair loss treatment.
Stay updated on our latest developments and innovations as we work to change the future of hair restoration.
Learn More
For more information on CytoMesopecia, AGF39™, and our other treatments, visit our official website: www.aesmed.co.kr
